Dietary carbohydrate restriction in type 2 diabetes mellitus and metabolic syndrome: time for a critical appraisal

1743-7075-5-9 1743-7075 Review Dietary carbohydrate restriction in type 2 diabetes mellitus and metabolic syndrome: time for a critical appraisal Accurso Anthony anthony.accurso@downstate.edu Bernstein K Richard md@diabetesscientist.com Dahlqvist Annika annika.dahlqvist@telia.com Draznin Boris Boris.Draznin@va.gov Feinman D Richard rfeinman@downstate.edu Fine J Eugene efine@downstate.edu Gleed Amy amy.gleed@downstate.edu Jacobs B David david.jacobs@downstate.edu Larson Gabriel gabriel.larson@downstate.edu Lustig H Robert rlustig@peds.ucsf.edu Manninen H Anssi anssi.manninen@gmail.com McFarlane I Samy sammy.mcfarlane@downstate.ed Morrison Katharine morrisons@ballochmyle.wanadoo.co.uk Nielsen Vesti Jørgen jvesti_nielsen@hotmail.com Ravnskov Uffe ravnskov@tele2.se Roth S Karl KarlRoth@creighton.edu Silvestre Ricardo blue_ricardo@yahoo.com Sowers R James sowersj@health.missouri.edu Sundberg Ralf ralfsundberg@telia.com Volek S Jeff Jeff.volek@uconn.edu Westman C Eric westm001@mc.duke.edu Wood J Richard rwood@spfldcol.edu Wortman Jay jwortman@interchange.ubc.ca Vernon C Mary mvernonmd@yahoo.com

State University of New York Downstate Medical Center, Brooklyn, New York, USA

New York Diabetes Center, Mamaroneck, New York, USA

Private Practice, Njurunda, Sweden

University of Colorado Health Sciences Center, Denver, Colorado, USA

Albert Einstein College of Medicine, Bronx, New York, USA

Division of Pediatric Endocrinology, University of California Medical Center, San Francisco, California, USA

Manninen Nutraceuticals Oy, Oulu, Finland

Ballochmyle Medical Group, Mauchline Ayrshire, UK

County Hospital, Karlshamn, Sweden

Independent Researcher, Lund, Sweden

Department of Pediatrics, Creighton University, Omaha, Nebraska, USA

Portuguese Sports Institute, Cruz Quebrada, Portugal

Cosmopolitan International Diabetes Center, University of Missouri, Columbia, Missouri, USA

Slottsstadens Läkarhus, Malmö, Sweden

Department of Kinesiology, University of Connecticut, Storrs, Connecticut, USA

Lifestyle Medicine Clinic, Duke University Medical Center, Durham, North Carolina, USA

Springfield College, Springfield, Massachusetts, USA

Health Canada, First Nations Division, Vancouver, British Columbia, Canada

Private Practice, Lawrence, Kansas, USA

Nutrition & Metabolism 1743-7075 2008 5 1 9 http://www.nutritionandmetabolism.com/content/5/1/9 18397522 10.1186/1743-7075-5-9 17 3 2008 08 4 2008 08 4 2008 2008 Accurso et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Current nutritional approaches to metabolic syndrome and type 2 diabetes generally rely on reductions in dietary fat. The success of such approaches has been limited and therapy more generally relies on pharmacology. The argument is made that a re-evaluation of the role of carbohydrate restriction, the historical and intuitive approach to the problem, may provide an alternative and possibly superior dietary strategy. The rationale is that carbohydrate restriction improves glycemic control and reduces insulin fluctuations which are primary targets. Experiments are summarized showing that carbohydrate-restricted diets are at least as effective for weight loss as low-fat diets and that substitution of fat for carbohydrate is generally beneficial for risk of cardiovascular disease. These beneficial effects of carbohydrate restriction do not require weight loss. Finally, the point is reiterated that carbohydrate restriction improves all of the features of metabolic syndrome.

Background

The epidemic of diabetes continues unabated, and impassioned calls for better treatment and prevention strategies are common features of scientific conferences. While it is generally acknowledged that total dietary carbohydrate is the major factor in glycemic control, strategies based on reduction of dietary carbohydrate have received little support. The American Diabetes Association, for example, has traditionally recommend against low carbohydrate diets (less than 130 g/day1; while the most recent guidelines 2 admit such diets as an alternative approach to weight loss, they continue to emphasize concerns and downplay benefits. Similarly, the Diabetes and Nutrition Study Group of the European Association for the Study of Diabetes 3 reported "no justification for the recommendation of very low carbohydrate diets in persons with diabetes." We feel, however, that there is ample evidence to warrant an alternative perspective and that diets based on carbohydrate restriction should be re-evaluated in light of current understanding of the underlying biochemistry and available clinical data.

Whatever success low fat dietary approaches have had in improving diabetes is to be applauded but it is reasonable for patients to be aware of the potential benefits of an alternative approach which we present here. The key feature is that low carbohydrate diets are based on mechanism. That is, glucose directly or indirectly through insulin, is a major control element in gluconeogenesis, glycogen metabolism, lipolysis and lipogenesis. The downstream stimulus-response processes are a current research interest (see e.g. 45) but, according to the view considered here, dietary fat has a generally passive role and deleterious effects of fat are almost always seen in the presence of high carbohydrate.

While low carbohydrate diets may not be appropriate for everyone, choices should be left to individual physicians and patients. Key points that bear on the assessment of benefit vs. risk of carbohydrate restriction are presented below. The discussion focuses on type 2 diabetes but many of the principles will apply to metabolic syndrome and possibly to type 1 as well67.

1. Carbohydrate restriction improves glycemic control, the primary target of nutritional therapy and reduces insulin fluctuations.

2. Carbohydrate-restricted diets are at least as effective for weight loss as low-fat diets.

3. Substitution of fat for carbohydrate is generally beneficial for markers for and incidence of CVD.

4. Carbohydrate restriction improves the features of metabolic syndrome.

5. Beneficial effects of carbohydrate restriction do not require weight loss.

Carbohydrate restriction is an intuitive and rational approach to improvement of glycemic and metabolic control. Data demonstrating that weight loss and cardiovascular risk are also improved remove these barriers to the acceptance of carbohydrate restriction as a reasonable if not the preferred treatment for type 2 diabetes. Finally, carbohydrate restriction is a potentially favorable diet for improving components of the metabolic syndrome and thereby for the prevention of diabetes.

1. Carbohydrate restriction improves glycemic control, the primary target of nutritional therapy and reduces insulin fluctuations

Figure 1 shows glycemic and insulin responses in a carefully controlled inpatient comparison of 10 obese patients with type 2 diabetes8. Fourteen days of a low-carbohydrate diet led to a mean decrease in energy intake of approximately 1000 kcal/d, a reduction in plasma glucose levels and average hemoglobin A1c (HbA_1c) from 7.3% to 6.8%. Insulin sensitivity improved by approximately 75%. No adverse effects were reported, and the carbohydrate that was removed was not replaced by substantial protein or fat.

Figure 1

Glucose and Insulin response for patients with type 2 diabetes on low carbohydrate diet vs. control

Glucose and Insulin response for patients with type 2 diabetes on low carbohydrate diet vs. control. Data (means ± SE) are for 9 patients with type 2 diabetes after seven days on their usual high-carbohydrate diet (control) and after 2 weeks) on a low-carbohydrate diet. Medication was reduced in 4 patients and discontinued in one during the low-carbohydrate diet. Figure redrawn from Boden, et al. [8].

Dashti, et al. showed dramatic and sustained reduction in blood glucose in 31 obese diabetic patients on a ketogenic diet over 56 weeks. Normal levels were reached by week 48 9. Similarly, Nielsen, et al.10 reported that a 20% carbohydrate diet was superior to a 55–60% carbohydrate diet with regard to bodyweight, glycemic control and reduction in HbA_1c. At follow-up, after 22 months, HbA_1cremained improved. In a 16-week pilot study of Yancy, et al., 21 overweight participants with type 2 diabetes showed a mean decrease in HbA_1cfrom 7.4% to 6.3%.

These results are not isolated. Many studies have demonstrated the benefits of carbohydrate reduction 111213141516 on glycemic control. Reaven, Garg, Grundy and coworkers have shown benefits of even moderate carbohydrate reduction, from 55% to 40%1718.

Reduction or elimination of medication

A striking effect of carbohydrate restriction is reduction or elimination of medication. Table 1 shows results from Yancy, et al. 19 in which 17 of 21 patients with type 2 diabetes reduced or discontinued diabetes medication upon carbohydrate restriction. Similar results were found by Boden 8 and Nielsen 1020. Practitioners have pointed out the need to reduce medication in advance of undertaking a low carbohydrate diet 6102021 highlighting the power of carbohydrate restriction to bring about the same therapeutic effect as drugs.

Table 1

Changes in diabetes medication of 19 overweight participants with type 2 diabetes who underwent a 16-week diet intervention trial. Patients were provided with VLCKD counseling with an initial goal of <20 g carbohydrate/day. Medication was reduced at diet initiation. Data from Yancy, et al. [62].

Patient number

Daily Dose – Week 0

Daily Dose – Week 16

Medications discontinued (n = 7 of 19 originally on medication)

glipizide 10 mg

none

metformin 1000 mg

metformin 1500 mg

none

metformin 1000 mg

none

metformin 1000 mg

none

metformin 1000 mg

none

metformin 1000 mg

none

Medications reduced (n = 10 of 19)

70/30 insulin 50 units

metformin 1000 mg

metformin 2000 mg

glyburide 20 mg

metformin 2000 mg

pioglitazone 45 mg

glypizide 20 mg

metformin 1500 mg

metformin 1000 mg

pioglitazone 30 mg

NPH 145 units

NPH 25 units

metformin 1000 mg

70/30 insulin 70 units

70/30 insulin 35 units

metformin 2550 mg

70/30 insulin 110 units

70/30 insulin 80 units

pioglitazone 45 mg

metformin 1000 mg

NPH 70 units, r 30 units

NPH 8 units

metformin 2000 mg

pioglitazone 45 mg

70/30 insulin 86 units

70/30 insulin 18 units

metformin 2000 mg

NPH insulin 90 units

NPH insulin 30 units

lispro insulin 90 units

glypizide 20 mg

2. Carbohydrate-restricted diets are at least as effective for weight loss as low-fat diets

Low-carbohydrate diets generally perform better than low-fat diets for weight loss in normal subjects, and patients with metabolic syndrome or diabetes 22232425. Studies by Foster, et al. 26 and Samaha, et al. 27 are often cited as examples where low carbohydrate diets are more effective at 6 months but no better than low-fat diets at 1 year. The experimental design, however, allowed re-introduction of carbohydrate in the low carbohydrate group as the study proceeded. Even if there were equal weight loss at one year, other physiologic markers, particularly TG and HDL, were greatly improved on the low-carbohydrate diet compared with the high carbohydrate diet as shown in Figure 2.

Figure 2

Comparison of low and high carbohydrate diets at 6 and 12 months

Comparison of low and high carbohydrate diets at 6 and 12 months. Results from a multi-center trial in which 63 obese men and women were randomly assigned to either diet. Data from Foster, et al. [26]. Figure from Volek & Feinman [24], used with permission. DBP, diastolic blood pressure; TAG, triglycerides.

3. Substitution of fat for carbohydrate is generally beneficial for markers for and incidence of CVD

The diet-heart hypothesis states that dietary fat, or at least saturated fat, promotes CVD. There are, however, numerous counter-examples and the popular and scientific literature has seriously challenged many of the underlying assumptions of the hypothesis 282930313233. In fact, total fat in the diet is not associated with an increase in CVD, as shown by experiments going back to Ancel Keys's Seven Country Study 34and, most recently and dramatically, the Women's Health Initiative 35.

Lipid markers for CVD

Clinically significant elevation of LDL-cholesterol is generally considered a primary indicator of CVD risk but interpretation must be tempered by the effect of particle size: small dense LDL particles are significantly more atherogenic than large, buoyant LDL particles 3637. Krauss, et al. identified a genetically influenced pattern (B) in people with higher levels of the smaller particles and found a strong linear relation between carbohydrate intake and prevalence of the atherogenic pattern B phenotype. Thus, replacing dietary fat with carbohydrate tends to worsen LDL size distribution for most of the population3637.

Other factors, such as high triglyceride (TG) and low HDL, are independent markers of insulin resistance and CVD risk. Indeed, the triglyceride:HDL ratio has been posited to be a surrogate measure of insulin resistance 38. This ratio is frequently exacerbated under conditions that lower LDL 24. An increase in apolipoprotein B (apoB) may be a preferred marker since each atherogenic lipoprotein particle contains one molecule of apoB; total LDL would bias results towards lower risk 39. There is also strong evidence that the apoB/apoA-I ratio is superior to conventional cholesterol ratios 39 as a predictor of CVD risk. Of particular importance is circulating TG because of its mechanistic link to the formation of atherogenic particles 4041, and its responsiveness to dietary manipulation. There is probably no dietary outcome as reliable as the reduction in TG due to carbohydrate restriction41.

The role of saturated fat

A primary goal of current recommendations is to put limits on dietary saturated fat but published results are inconsistent (see e.g. 42). Several critical reviews have pointed up the general failure to meet the kind of unambiguous outcomes that would justify blanket condemnation of saturated fat, per se 2930414344. Notably, during the obesity and diabetes epidemic, the proportion of dietary saturated fat decreased. In men, the absolute amount decreased by 14%. Similarly, the WHI revealed no difference in CVD incidence for people who consumed < 10% saturated fat or those whose consumption was > 14%35. Dreon, et al. 44 showed that increased saturated fat lead to a decrease in small, dense LDL. Perhaps most remarkable was a study by Mozaffarian 45 which showed that greater intake of saturated fat was associated with reduced progression of coronary atherosclerosis; greater carbohydrate intake was linked to increased progression.

In our view, inconsistencies in the experimental results with dietary saturated fat arise from a failure to distinguish between replacement by unsaturated fat or by carbohydrate 3. In the former case, there is usually improvement in CVD risk or outcome (although it is not excluded that this is due to the effect of the unsaturated fat rather than reduction in the risk from the saturated fat). Replacement of saturated fat with carbohydrate, however, is almost always deleterious 4647. Again, the idea that carbohydrate is a control element determining the fate of ingested lipid is overriding.

The assumption that the dietary fatty acid profile is reflected in plasma distribution is not always true, especially for saturated fatty acids which seems to be subject to much metabolic processing 42. It was also expected that an increase in total fat might show changes in lipid pattern but Raatz, et al. showed that such differences were extremely small between a low fat and high fat diet 48. A recent report comparing two low-CHO groups that differed in dietary SFA showed little difference in plasma levels of stearic or palmitic acid 49. Most telling, Volek's group compared a VLCK diet (% CHO:fat 12:59) with a low-fat (LF) diet (56:24) and found that after 12 weeks, SFA in TG and cholesteryl ester were lower in the VLCK group than the LF group even thought the low carbohydrate group had a 3-fold higher intake of dietary SFA 50.

4. Carbohydrate restriction improves the features of metabolic syndrome

An important idea guiding current medical thinking is that clustering of seemingly disparate physiologic states, obesity, atherogenic dyslipidemia, hyperglycemia and hypertension, termed metabolic syndrome (MetS) suggests a common underlying cause. Inherent in this concept lies the possibility that treating one risk factor or disease state might confer benefit for risk of other diseases. A recent review showed that carbohydrate restriction improves all of these markers24. Indeed, metabolic syndrome might be consistently defined as those physiologic markers that respond to reduction in dietary carbohydrate. Metabolic syndrome might be seen as a generalization of the carbohydrate intolerance that characterizes frank diabetes24.

In a prospective study testing the hypothesis linking carbohydrate restriction to MetS, the carbohydrate-restricted group showed greater improvements in weight loss and multiple markers of atherogenic dyslipidemia (increased HDL and LDL diameter and reductions in TG and apo B/apo A1 ratio) compared to a low fat arm. Unexpectedly, the carbohydrate-restricted arm, with three times greater dietary saturated fat, showed a reduction in plasma saturated fat, while plasma saturated fat in the low-fat arm remained unchanged 50.

Similarly, Petersen, et al. 51 showed that ingestion of a high carbohydrate meal led to a greater increase in de novo fatty acid synthesis and hepatic triglyceride formation in insulin-resistant men compared to a similar group of insulin-sensitive controls. Carbohydrate-induced atherogenic dyslipidemia is thus enhanced by insulin resistance.

Carbohydrate restriction will generally reduce the consumption of fructose, which makes up half the mass of common sweeteners (high-fructose corn syrup or sucrose). Fructose consumption has been implicated in the epidemics of obesity, MetS, and type 2 diabetes and is known to induce hypertension, de novo lipogenesis, hepatic insulin resistance and adiposity 525354.

In summary, carbohydrate restriction is one of the few common interventions that targets all of the features of MetS. If such a straight-forward approach can alleviate a condition for which there is no known effective drug, its potential should be vigorously explored.

5. Beneficial effects of carbohydrate restriction do not require weight loss

Obesity is commonly considered a cause of insulin resistance. Obesity, however, does not occur spontaneously. Obesity is a response. The effects of obesity that lead to insulin resistance in peripheral tissues, largely increased fatty acids, are downstream from the primary impact of diet. This argues for an emphasis of treatment on glycemic control and improved hepatic metabolism rather than weight loss. A simpler alternative hypothesis considers that insulin resistance represents a down-regulation of hormonal response as a result of persistent high levels of insulin, a feature common to other hormonal systems 55. In this view, diabetes, obesity and the components of MetS are parallel effects of hyperinsulinemia and/or hyperglycemia.

The finding that lipid improvements seen in carbohydrate-restricted diets persist even after no further weight loss (Figure 2) suggests that the benefit of carbohydrate restriction is independent of weight loss. Two additional lines of evidence support this idea:

1) In experiments in which body mass is kept constant in normal-weight men56or patients with type 2 diabetes1113, a very low carbohydrate diet resulted in dramatic improvements in triglycerides and HDL cholesterol with minimal change in body mass.

2) Experiments in which change in macronutrients and weight loss are separated in time show that eucaloric carbohydrate reduction leads to greater improvement in atherogenic lipid markers (TG, HDL, apoB/apoA1 and mean LDL particle size) even in the presence of higher saturated fat5758. A low fat diet, however, required weight loss to achieve effective improvement in the lipid profile (Figure 3). Notably, the sum of the two effects showed that eucaloric carbohydrate restriction plus weight loss was more effective than eucaloric low fat plus weight loss.

Figure 3

Effect of dietary interventions on reduction in triglycerides

Effect of dietary interventions on reduction in triglycerides. Eucaloric diets of indicated carbohydrate content were begun at time 0. At week 3, a 1000 kcal reduction in energy was implemented and at week 9, dieters were put on maintenance diet. Combined effect of calorie reduction and maintenance are reported at week 12. Solid Lines: data from Krauss, et al. [58] were converted from reported log values in their Table 2 and per cent of baseline was calculated. Dashed line: data from Sharman, et al [56]: A eucaloric ketogenic diet was instituted for six weeks (no weight loss phase). Points were recorded at week 3 and 6. Figure modified from Feinman & Volek [57]. Similar results were found for HDL, apoB/apoA1 and other markers of CVD [57, 58]

Practical considerations and recommendations

Definitions and recommendations

Response to carbohydrate restriction shows both continuous, graded outcomes 1718 as well as a threshold effects. LDL particle size, e.g. appears to depend linearly on the level of dietary carbohydrate3637. On the other hand, many studies show maximum benefit for very low carbohydrate intake; the early phases of popular low carbohydrate diets target such very low levels 615215960. The principle rests on the concept of a catalytic or threshold effect for insulin in shifting the body from an anabolic state to fat oxidation. The tipping point is empirically taken as the onset of ketonuria, also used as an indicator of compliance with a very low carbohydrate ketogenic diet (VLCKD). The threshold carbohydrate reduction for ketonuria varies among individuals, but a rough estimate is 50 g of carbohydrate per day or, approximately 10% of energy on a nominal 2000 kcal diet, (a target of 30 g/d is common in the early phases of popular VLCKD diets)152160.

We suggest the following definitions:

The ADA designates low carbohydrate diets as less than 130 g/d or 26% of a nominal 2000 kcal diet and we consider this a reasonable cutoff for the definition of a low-carbohydrate diet. Carbohydrate consumption before the epidemic of obesity averaged 43%, and we suggest 26% to 45% as the range for moderate-carbohydrate diets. The intake of less than 30 g/d, as noted above should be referred to as a very low carbohydrate ketogenic diet (VLCKD). The term Ketogenic Diet should be reserved for the therapeutic approach to epilepsy. These diets do not independently specify the level of carbohydrate, but rather the sum of carbohydrate and protein.

In practice, many low carbohydrate dieters do not add additional fat. First shown by LaRosa, 61 it has now been observed by many other investigators. 86263 A reduced carbohydrate diet may show significant per cent increase in fat, but there may be no change in the absolute amount consumed. Not everybody on a low carbohydrate diet follows this pattern, but a recommendation based on this behavior would seem more appropriate than unqualified rejection of low-carbohydrate diets.

While some proponents of carbohydrate restriction for the management of diabetes favor sustained adherence to very low levels of carbohydrate intake 6, all options may be considered and therapeutic choices can be determined by individual physicians and their patients

The term low-carbohydrate diet is frequently taken as synonymous with the popular Atkins diet60 which remains highly controversial. Carbohydrate control, however, has many implementations and the severity of the epidemic of diabetes makes it appropriate to go beyond historical controversy and analyze dietary interventions as they are actually implemented.

There is reluctance to make recommendations for low carbohydrate diets on the grounds that people will not follow them but compliance and efficacy of dietary recommendations are separate phenomena. In fact, all recommendations are specifically intended to be different from average consumption1 and it is sensibly the purpose of health agencies to encourage conformance to the best therapies.

It is time to re-appraise the role of carbohydrate restriction. Although pessimism exists in the medical community on the efficacy of any diet in the treatment of diabetes 2 and MetS, the success of carbohydrate restriction for many practitioners and individual patients64 mandates that we should determine how this approach can be consistently and effectively employed.

Finally, while no systematic study of clinical practice has been done, anecdotal evidence suggests that carbohydrate restriction is a common clinical recommendation for diabetes. We believe that there is a need to codify these recommendations in light of current evidence.

Basic biochemistry, clinical experience and an evolving understanding of metabolic syndrome support the need for evaluation of the efficacy and safety of carbohydrate-restricted diets for the treatment of type 2 diabetes. The fact that carbohydrate restriction improves markers of cardiovascular health, even in the absence of weight loss, sensibly removes historical objections to the dangers of this approach. A critical re-appraisal could form the basis for an alternative for those patients for whom current recommendations are not successful.

Competing interests

MCV has been a consultant for Atkins Nutritionals, Inc. All other authors declare that they have nothing to declare.

Authors' contributions

RDF wrote the first version of this article based on published material and correspondence with the other authors who modified and approved the final version.

Abbreviations

apo B, apolipoprotein B; apo A1, apolipoprotein A1: CVD, cardiovascular disease; HbA1c, hemoglobin A1c; HDL, high density lipoprotein; LDL, low density lipoprotein; MetS, metabolic syndrome; SFA, saturated fatty acids; TG, triglycerides (triacylglycerol); VLCKD (VLCK diet), very low carbohydrate ketogenic diet.

Nutrition Recommendations and Interventions for Diabetes-2007 American Diabetes Association Diabetes Care 2007 30 Suppl 1 S48 S65 10.2337/dc07-S048 17192379 Nutrition Recommendations and Interventions for Diabetes-2008 American Diabetes Association Diabetes Care 2008 31 Suppl 1 S61 S78 10.2337/dc08-S061 18165339 Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus Mann JI De Leeuw I Hermansen K Karamanos B Karlstrom B Katsilambros N Riccardi G Rivellese AA Rizkalla S Slama G Nutr Metab Cardiovasc Dis 2004 14 6 373 394 10.1016/S0939-4753(04)80028-0 15853122 Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85alpha: the two sides of a coin Draznin B Diabetes 2006 55 8 2392 2397 10.2337/db06-0391 16873706 Atherosclerosis in diabetes and insulin resistance Reusch JE Draznin BB Diabetes Obes Metab 2007 9 4 455 463 10.1111/j.1463-1326.2006.00620.x 17587387 Bernstein R Dr. Bernstein's Diabetes Solution: The Complete Guide to Achieving Normal Blood Sugars Little, Brown and Company 2007 A low carbohydrate diet in type 1 diabetes: clinical experience – a brief report Nielsen JV Jönsson E Ivarsson A Ups J Med Sci 2005 110 3 267 273 16454166 Effect of a low-carbohydrate diet on appetite, blood glucose levels, and insulin resistance in obese patients with type 2 diabetes Boden G Sargrad K Homko C Mozzoli M Stein TP Ann Intern Med 2005 142 6 403 411 15767618 Beneficial effects of ketogenic diet in obese diabetic subjects Dashti HM Mathew TC Khadada M Al-Mousawi M Talib H Asfar SK Behbahani AI Al-Zaid NS Mol Cell Biochem 2007 17447017 Low-carbohydrate diet in type 2 diabetes. Stable improvement of bodyweight and glycaemic control during 22 months follow-up Nielsen JV Jönsson EA Nutr Metab (Lond) 2006 3 1 22 1526736 16774674 10.1186/1743-7075-3-22 A low-carbohydrate/high-fat diet improves glucoregulation in type 2 diabetes mellitus by reducing postabsorptive glycogenolysis Allick G Bisschop PH Ackermans MT Endert E Meijer AJ Kuipers F Sauerwein HP Romijn JA J Clin Endocrinol Metab 2004 89 12 6193 6197 10.1210/jc.2004-1041 15579777 Short-term effects of severe dietary carbohydrate-restriction advice in Type 2 diabetes – a randomized controlled trial Daly ME Paisey R Paisey R Millward BA Eccles C Williams K Hammersley S MacLeod KM Gale TJ Diabet Med 2006 23 1 15 20 10.1111/j.1464-5491.2005.01760.x 16409560 Control of blood glucose in type 2 diabetes without weight loss by modification of diet composition Gannon MC Nuttall FQ Nutr Metab (Lond) 2006 3 16 1475800 16556307 10.1186/1743-7075-3-16 Clinical Experience of a Carbohydrate-Restricted Diet: Effect on Diabetes Mellitus Vernon M Mavropoulos J Transue M Yancy W Jr Westman E Metabolic Syndrome and Related Disorders 2003 1 233 237 10.1089/154041903322716714 Vernon MC Eberstein JA Atkins Diabetes Revolution. The Groundbreaking Approach to Preventing and Controlling Type 2 Diabetes New York: William Morrow 2004 A Pilot trial of a Low-Carbohydrate, Ketogenic Diet in Patients with Type 2 Diabetes Yancy WS Jr Vernon MC Westman EC Metabolic Syndrome and Related Disorders 2003 1 3 239 243 10.1089/154041903322716723 Effect of dietary carbohydrate on the metabolism of patients with non-insulin dependent diabetes mellitus Reaven GM Nutr Rev 1986 44 2 65 73 3703391 Effects of varying carbohydrate content of diet in patients with non-insulin-dependent diabetes mellitus Garg A Bantle JP Henry RR Coulston AM Griver KA Raatz SK Brinkley L Chen YD Grundy SM Huet BA JAMA 1994 271 18 1421 1428 10.1001/jama.271.18.1421 7848401 Insulin Resistance from a Low-Carbohydrate, High Fat Diet Perspective Westman EC Yancy WS Jr Haub MD Volek JS Metabolic Syndrome and Related Disorders 2005 3 3 7 10.1089/met.2005.3.14 Lasting improvement of hyperglycaemia and bodyweight: low-carbohydrate diet in type 2 diabetes – a brief report Nielsen JV Jonsson E Nilsson AK Ups J Med Sci 2005 110 1 69 73 15801687 Eades MR Eades MD Protein Power New York: Bantam Books 1996 Thermodynamics and Metabolic Advantage of Weight Loss Diets Feinman RD Fine EJ Metabolic Syndrome and Related Disorders 2003 1 3 209 219 10.1089/154041903322716688 Effects of variation in protein and carbohydrate intake on body mass and composition during energy restriction: a meta-regression 1 Krieger JW Sitren HS Daniels MJ Langkamp-Henken B Am J Clin Nutr 2006 83 2 260 274 16469983 Carbohydrate restriction improves the features of Metabolic Syndrome. Metabolic Syndrome may be defined by the response to carbohydrate restriction Volek JS Feinman RD Nutr Metab (Lond) 2005 2 31 1323303 16288655 10.1186/1743-7075-2-31 Low-carbohydrate nutrition and metabolism Westman EC Feinman RD Mavropoulos JC Vernon MC Volek JS Wortman JA Yancy WS Phinney SD Am J Clin Nutr 2007 86 2 276 284 17684196 A randomized trial of a low-carbohydrate diet for obesity Foster GD Wyatt HR Hill JO McGuckin BG Brill C Mohammed BS Szapary PO Rader DJ Edman JS Klein S N Engl J Med 2003 348 21 2082 2090 10.1056/NEJMoa022207 12761365 A low-carbohydrate as compared with a low-fat diet in severe obesity Samaha FF Iqbal N Seshadri P Chicano KL Daily DA McGrory J Williams T Williams M Gracely EJ Stern L N Engl J Med 2003 348 21 2074 2081 10.1056/NEJMoa022637 12761364 Colpo A The Great Cholesterol Con Lulu Press 2006 Saturated fats: what dietary intake? German JB Dillard CJ Am J Clin Nutr 2004 80 3 550 559 15321792 Carbohydrate Restriction and Cardiovascular Risk Karam J Nessim F McFarlane S Feinman R Current Cardiovascular Risk Reports 2008 2 2 88 94 10.1007/s12170-008-0018-z Ravnskov U The Cholesterol Myths: Exposing the Fallacy that Cholesterol and Saturated Fat Cause Heart Disease Washington, DC: New Trends Publishing, Inc 2000 Taubes G Good Calories, Bad Calories New York: Alfred A. Knopf 2007 The case for not restricting saturated fat on a low carbohydrate diet Volek JS Forsythe CE Nutr Metab (Lond) 2005 2 21 1208952 16135250 10.1186/1743-7075-2-21 Coronary heart disease in seven countries Keys A 1970 41 Suppl 1 211 Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial Howard BV Van Horn L Hsia J Manson JE Stefanick ML Wassertheil-Smoller S Kuller LH LaCroix AZ Langer RD Lasser NL JAMA 2006 295 6 655 666 10.1001/jama.295.6.655 16467234 Low-density lipoprotein subclass patterns and lipoprotein response to a reduced-fat diet in men Dreon DM Fernstrom HA Miller B Krauss RM FASEB J 1994 8 1 121 126 8299884 Atherogenic lipoprotein phenotype and diet-gene interactions Krauss RM J Nutr 2001 131 2 340S 343S 11160558 Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? McLaughlin T Reaven G Abbasi F Lamendola C Saad M Waters D Simon J Krauss RM Am J Cardiol 2005 96 3 399 404 10.1016/j.amjcard.2005.03.085 16054467 Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel Barter PJ Ballantyne CM Carmena R Castro Cabezas M Chapman MJ Couture P de Graaf J Durrington PN Faergeman O Frohlich J J Intern Med 2006 259 3 247 258 10.1111/j.1365-2796.2006.01616.x 16476102 Regulation of plasma triglycerides in insulin resistance and diabetes Ginsberg HN Zhang YL Hernandez-Ono A Arch Med Res 2005 36 3 232 240 10.1016/j.arcmed.2005.01.005 15925013 Modification of lipoproteins by very low-carbohydrate diets Volek JS Sharman MJ Forsythe CE J Nutr 2005 135 6 1339 1342 15930434 Dietary fat, fatty acid composition in plasma and the metabolic syndrome Vessby B Curr Opin Lipidol 2003 14 1 15 19 10.1097/00041433-200302000-00004 12544656 The questionable role of saturated and polyunsaturated fatty acids in cardiovascular disease Ravnskov U J Clin Epidemiol 1998 51 6 443 460 10.1016/S0895-4356(98)00018-3 9635993 Change in dietary saturated fat intake is correlated with change in mass of large low-density-lipoprotein particles in men Dreon DM Fernstrom HA Campos H Blanche P Williams PT Krauss RM Am J Clin Nutr 1998 67 5 828 836 9583838 Dietary fats, carbohydrate, and progression of coronary atherosclerosis in postmenopausal women Mozaffarian D Rimm EB Herrington DM Am J Clin Nutr 2004 80 5 1175 1184 1270002 15531663 Dietary fat intake and the risk of coronary heart disease in women Hu FB Stampfer MJ Manson JE Rimm E Colditz GA Rosner BA Hennekens CH Willett WC N Engl J Med 1997 337 21 1491 1499 10.1056/NEJM199711203372102 9366580 Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials Mensink RP Zock PL Kester AD Katan MB Am J Clin Nutr 2003 77 5 1146 1155 12716665 Total fat intake modifies plasma fatty acid composition in humans Raatz SK Bibus D Thomas W Kris-Etherton P J Nutr 2001 131 2 231 234 11160538 Effects of low carbohydrate diets high in red meats or poultry, fish and shellfish on plasma lipids and weight loss Cassady B Charboneau N Brys E Crouse K Beitz D Wilson T Nutr Metab (Lond) 2007 4 23 2174488 17974023 Comparison of low fat and low carbohydrate diets on circulating Fatty Acid composition and markers of inflammation Forsythe CE Phinney SD Fernandez ML Quann EE Wood RJ Bibus DM Kraemer WJ Feinman RD Volek JS Lipids 2008 43 1 65 77 10.1007/s11745-007-3132-7 18046594 Inaugural Article: The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome Petersen KF Dufour S Savage DB Bilz S Solomon G Yonemitsu S Cline GW Befroy D Zemany L Kahn BB Proc Natl Acad Sci USA 2007 104 31 12587 12594 1924794 17640906 10.1073/pnas.0705408104 Metabolic effects of fructose Le KA Tappy L Curr Opin Nutr Metab Care 2006 9 4 469 475 16778579 Fructose and the metabolic syndrome: pathophysiology and molecular mechanisms Rutledge AC Adeli K Nutr Rev 2007 65 6 S13 S23 10.1301/nr.2007.jun.S13-S23 17605309 Insulin stimulation of hepatic triacylglycerol secretion in the insulin-replete state: implications for the etiology of peripheral insulin resistance Zammit VA Ann N Y Acad Sci 2002 967 52 65 12079835 Childhood obesity: behavioral aberration or biochemical drive? Reinterpreting the First Law of Thermodynamics Lustig RH Nature Clin Pract Endo Metab 2006 2 8 447 458 10.1038/ncpendmet0220 16932334 A ketogenic diet favorably affects serum biomarkers for cardiovascular disease in normal-weight men Sharman MJ Kraemer WJ Love DM Avery NG Gomez AL Scheett TP Volek JS J Nutr 2002 132 7 1879 1885 12097663 Low carbohydrate diets improve atherogenic dyslipidemia even in the absence of weight loss Feinman RD Volek JS Nutr Metab (Lond) 2006 3 24 1488852 16790045 10.1186/1743-7075-3-24 Separate effects of reduced carbohydrate intake and weight loss on atherogenic dyslipidemia Krauss RM Blanche PJ Rawlings RS Fernstrom HS Williams PT Am J Clin Nutr 2006 83 5 1025 1031 16685042 Agatston A The South Beach Diet New York: Random House 2003 Atkins RC Dr. Atkins' New Diet Revolution New York: Avon Books 2002 Effects of high-protein, low-carbohydrate dieting on plasma lipoproteins and body weight Larosa JC Fry AG Muesing R Rosing DR J Am Diet Assoc 1980 77 3 264 270 7410754 A low-carbohydrate, ketogenic diet to treat type 2 diabetes Yancy WS Jr Foy M Chalecki AM Vernon MC Westman EC Nutr Metab (Lond) 2005 2 34 1325029 16318637 10.1186/1743-7075-2-34 Comparison of energy-restricted very low-carbohydrate and low-fat diets on weight loss and body composition in overweight men and women Volek JS Sharman MJ Gomez AL Judelson DA Rubin MR Watson G Sokmen B Silvestre R French DN Kraemer WJ Nutr Metab (Lond) 2004 1 1 13 538279 15533250 10.1186/1743-7075-1-13 Low carbohydrate diets in family practice: what can we learn from an internet-based support group Feinman RD Vernon MC Westman EC Nutr J 2006 5 26 1609174 17014706 10.1186/1475-2891-5-26